Well, there is some discussion that advanced PCa in its early stage, oligo-metastatic may be cured.

Put me in the other camp, no.

So, what to do with your clinical data. Were it me, nothing, continue to actively monitor, discuss with my medical team what clinical data would constitute sufficient data to resume treatment, then just live my life.

For my medical team and I, that criteria is:
Three (or more) PSA tests spaced three months apart that show an increase.
AND..,
PSA between .5-1.0

Why?

One, we want trends not isolated data points that can be unexplained.
Two, we feel PSA between .5-1.0 allows a statically significant chance of locating activity to inform our treatment decision, 2/3 vs 1/3 below that.
Three, we don't believe there is any risk involved on waiting to get that dara.

As to what's ahead? Well, that depends on the clinical data.

There is some discussion about the use of SBRT only to delay the need for systemic therapy.

It could be that you elect to do SBRT and systemic therapy -ADT + ARI for a defined period and come off and actively monitor again.

The latter is what I chose in my last treatment, SBRT + 12 months Orgovyx. We are 14 months since coming off that regimen, all quiet.

USPSA can give us early indication of treatment ahead, It can also lead us to excessive analysis...The data you describe were it mine would lead me to discuss with my medical team about "not now!"

Kevin